Chemically Programmed Immunity

描述 摘要： 想象一下，通过服用一粒简单的药丸，立即编程免疫系统的适应性和先天性武器来攻击肿瘤或病毒，从而调用T细胞，巨噬细胞和抗体发挥作用，预防感染并阻止疾病。这种方法可以应对生物医学研究和治疗中尚未解决的重大挑战。我的目标是开发新的方法，使先天和后天免疫有目的地针对感兴趣的病原体。这些研究建立在最近揭示的Toll样受体信号传导机制，关于将其传感能力靶向确定感兴趣的病原体的方法的想法以及从我们自己发明的化学编程抗体中获得的见解的基础上。最终，这些研究将使科学家能够编程各种免疫细胞和反应，以使用各种机制攻击感兴趣的病原体。我们将把这些结果应用于癌症治疗的研究。此外，我们还将探索新的方法，使共价疫苗诱导的循环免疫球蛋白能够抑制HIV-1和流感病毒的进入。从这些研究中产生的疫苗可能具有预防和治疗效用。我将开发新的化学方法，旨在学习如何有目的地将先天免疫，T细胞和巨噬细胞靶向定义的病原体。我将应用这些发展来创造新的癌症疗法。我将开发一种新的口服化学免疫方法。我将把口服化学程序免疫的发展应用于HIV-1和流感的新疫苗战略。

DESCRIPTION Abstract: Imagine calling T-cells, macrophages, and antibodies into action by taking a simple pill that instantaneously programs both adaptive and innate arms of the immune system to attack a tumor or virus, preventing infection and halting disease. Such an approach could meet major unmet challenges in biomedical research and therapy. My goal is to develop novel approaches that allow innate and acquired immunity to be purposefully targeted to pathogens of interest. These studies build on recently revealed mechanisms of Toll-like receptor signaling, ideas concerning approaches of targeting their sensing abilities to pathogens of defined interest and insights gained from our own invention of chemically programmed antibodies. Ultimately, these studies will allow scientists to program a variety of immune cells and responses to attack pathogens of interest using a variety of mechanisms. We will apply these results to studies in cancer therapy. Furthermore, we will explore novel approaches that should allow for circulating immunoglobulins induced with covalent vaccines to be programmed to inhibit HIV-1 and flu virus entry. The vaccines that result from these studies may be of both prophylactic and therapeutics utility. I will develop novel chemical approaches aimed at learning how to purposefully target innate immunity, T- cells, and macrophages to defined pathogens. I will apply these developments to create new cancer therapies. I will develop a novel approach to orally available chemically programmed immunity. I will apply developments in orally available chemically programmed immunity towards new vaccine strategies for HIV-1 and flu.